Editas Medicine (EDIT) Total Current Liabilities (2015 - 2025)
Editas Medicine (EDIT) posted quarterly Total Current Liabilities of $46.2 million for Q4 2025, down 40.12% year-over-year from $77.2 million in Q4 2024, and down 25.14% quarter-over-quarter from $61.8 million in Q3 2025.
Editas Medicine (EDIT) Total Current Liabilities (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Total Current Liabilities for 11 consecutive years, with $46.2 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Current Liabilities fell 40.12% year-over-year to $46.2 million; the TTM figure through Dec 2025 stood at $46.2 million (down 40.12% YoY), while the FY2025 annual figure was $46.2 million, down 40.12% from the prior year.
- Total Current Liabilities retreated to $46.2 million in Q4 2025 per EDIT's latest filing, from $61.8 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $77.2 million in Q4 2024 and bottomed at $36.4 million in Q2 2022.
- Historically, Total Current Liabilities has averaged $58.7 million across 5 years, with a median of $60.9 million in 2022.
- Annual changes were most pronounced in 2022 — Total Current Liabilities sank 44.83% — and 2023, when it surged 56.58%.
- Editas Medicine's Total Current Liabilities stood at $46.9 million in 2021, then gained by 28.21% to $60.1 million in 2022, then climbed by 5.17% to $63.2 million in 2023, then grew by 22.16% to $77.2 million in 2024, then slumped by 40.12% to $46.2 million in 2025.
- Business Quant data shows EDIT's Total Current Liabilities at $46.2 million in Q4 2025, $61.8 million in Q3 2025, and $65.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Editas Medicine | 263.01 Mn | 116.36 Mn | - | 46.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 46.25 Mn |
| Sep 30, 2025 | 61.77 Mn |
| Jun 30, 2025 | 65.94 Mn |
| Mar 31, 2025 | 73.11 Mn |
| Dec 31, 2024 | 77.23 Mn |
| Sep 30, 2024 | 72.35 Mn |
| Jun 30, 2024 | 74.31 Mn |
| Mar 31, 2024 | 66.49 Mn |
| Dec 31, 2023 | 63.22 Mn |
| Sep 30, 2023 | 58.60 Mn |
| Jun 30, 2023 | 54.51 Mn |
| Mar 31, 2023 | 57.16 Mn |
| Dec 31, 2022 | 60.11 Mn |
| Sep 30, 2022 | 42.29 Mn |
| Jun 30, 2022 | 36.42 Mn |
| Mar 31, 2022 | 36.50 Mn |
| Dec 31, 2021 | 46.88 Mn |
| Sep 30, 2021 | 50.91 Mn |
| Jun 30, 2021 | 66.02 Mn |
| Mar 31, 2021 | 64.01 Mn |